Bioequivalence Study of Oxcarbazepine Oral Suspension 300 mg/5mL Under Fed Condition

Mise à jour : Il y a 4 ans
Référence : NCT00951847

  • | Pays :
  • India
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The purpose of this study is to compare the single-dose oral bioavailability of oxcarbazepine 300 mg/5mL oral suspension of OHM Laboratories, USA (a subsidiary of Ranbaxy Pharmaceuticals Inc.) with Trileptal® 300 mg/5mL oral suspension (containing oxcarbazepine 300 mg/5mL) of Novartis Pharmaceutical Corporation, USA in healthy, adult, male, human subjects under fed conditions.


Critère d'inclusion

  • Healthy

Liens